Background In all, 20% of fine-needle aspiration (FNA) biopsies of thyroid nodules have an indeterminate diagnosis; of these, 80% are found to be benign after thyroidectomy. Some previous reports indicate that positron emission tomography (PET) with 18 F-fluorodeoxyglucose (FDG) imaging may predict malignancy status. We now report results on the first 51 patients in the largest prospective study of FDG-PET in patients with an indeterminate thyroid nodule FNA. Methods Eligible patients had a dominant thyroid nodule that was palpable or C1 cm in greatest dimension as seen by ultrasonography, and indeterminate histology of the FNA biopsy specimen. Participants underwent preoperative neck FDG-PET alone or FDG-PET with computed tomography (FDG-PET/CT). Images were evaluated qualitatively and semiquantitatively using the maximum standardized uptake value (SUV max ). Final diagnosis was determined by histopathologic analysis after thyroidectomy. Descriptive statistical analysis was performed. Results A total of 51 patients underwent preoperative FDG-PET or FDG-PET/CT. Studies without focally increased uptake localized to the lesion were considered negative. For all lesions (10 malignant, 41 benign), the sensitivity, specificity, positive-predictive value (PPV), and negative-predictive value (NPV) were 80%, 61%, 33%, and 93%, respectively. Postoperatively, two malignant and six benign lesions were found to be \1 cm by pathology examination; one lesion was not measured. When these lesions were excluded, the sensitivity, specificity, PPV, and NPV were 100%, 59%, 36%, and 100%, respectively. Conclusions Based on these preliminary data, FDG-PET may have a role in excluding malignancy in thyroid nodules with an indeterminate FNA biopsy. This finding justifies ongoing accrual to our target population of 125 participants.
Introduction
Fine-needle aspiration (FNA) biopsy remains the standard method for diagnosing a palpable thyroid nodule or a nodule with suspicious features seen by imaging criteria. Nodules with indeterminate FNA results remain a diagnostic dilemma because approximately 20-30% of these nodules will ultimately be found to be malignant by pathology examination after excision. However, nearly all patients with an FNA biopsy of indeterminate cytology undergo thyroid lobectomy, at a minimum, to establish the diagnosis. The definition of an indeterminate lesion by FNA cytology includes follicular lesions, Hurthle cell or oncocytic cell lesions, atypical cytology, abnormal cytology, or suspicious cytology. For nearly 80% of patients with benign disease, this surgery would be unnecessary if the diagnosis were established preoperatively. Although rare, complications from thyroid surgery can be serious or even life-threatening; such complications include recurrent laryngeal nerve injury, postoperative bleeding, hypoparathyroidism, and infection. Thus, the development of new diagnostic modalities to address these thyroid nodules with indeterminate cytology is an area of ongoing research worldwide.
Several previous studies examined the utility of positronemission tomography (PET) with 18 F-fluorodeoxyglucose (FDG) for detecting malignancy in thyroid nodules of indeterminate cytology. Reported sensitivity of FDG-PET to detect malignancy was 100% in four of five of these studies, with the remaining study reporting sensitivity of 57% [1] [2] [3] [4] [5] . The reported specificity ranged from 39% to 66%. One additional study evaluated the association between standardized uptake value (SUV) uptake over time and malignancy in follicular thyroid nodules by performing serial PET scans over a 2-h period and measuring the area under the SUV curve [6] . This study demonstrated no statistically significant difference between the mean area under the curve (AUC) for malignant versus benign cases, although there were significant differences in the dynamics of the change in SUV over time between these groups. Because of the considerable overlap in SUV AUC values between benign and malignant lesions in that study, the authors were unable to identify a cutoff value that would appropriately guide patient management. These studies enrolled modest numbers of participants, with sample sizes ranging from 15 to 44.
To date, it is unclear whether FDG-PET has diagnostic utility for thyroid nodules of indeterminate cytology. There may be specific patient or nodule characteristics that affect the accuracy of FDG-PET for distinguishing benign from malignant nodules, but they have been difficult to determine owing to the variability in patient characteristics and diagnostic criteria, coupled with the small sample sizes in the previous studies.
Presented here are data on the first 51 patients from the largest trial to date examining the utility of FDG-PET to distinguish malignancy in thyroid nodules found to have indeterminate cytology on FNA examination.
Materials and methods
This study was conducted with the approval of the Washington University Human Research Protection Office and the Radioactive Drug Research Committee, the St. Louis University Institutional Review Board, and the St. Louis VAMC Human Studies Subcommittee.
Patients
Patients were recruited prospectively from endocrine surgery or otolaryngology practices at Washington University, St. Louis University, and the St. Louis Veterans Administration Medical Center, John Cochran Division (St. Louis VAMC). Eligible patients were at least 18 years of age, had a solitary or dominant thyroid nodule that was palpable or measured C1 cm as seen by ultrasonography, and were scheduled for surgical excision. The minimum size criterion was established to address the limitations of spatial resolution of PET imaging and to avoid partial volume effect. Patients must have undergone FNA biopsy of the nodule of interest with any of the following results: follicular lesion, Hurthle cell or oncocytic cell lesion, atypical cytology, abnormal cytology, or suspicious cytology. Patients with a history of prior radiation treatment or surgical procedures in the neck were excluded owing to concerns of anatomical distortion on PET scans performed without computed tomography (CT). Patients with clinical or laboratory evidence of hyper-or hypothyroidism were excluded unless they were corrected to a clinically euthyroid state with a stable dose of appropriate medication prior to surgical evaluation.
Altogether, 86 patients were screened and found to be eligible by these criteria. Only 51 (41%) of the patients consented to participate and completed the study. One additional patient consented but refused PET scanning because of claustrophobia.
The anticipated target enrollment is 125 patients at study completion. With a 30% malignancy rate, this will provide power to estimate sensitivity of 0.90 with a 95% confidence interval (CI) of 0.75-0.97 and specificity of 0.90 with a 95% CI of 0.81-0.95.
FDG-PET or FDG-PET/CT
The PET imaging scanners used at Washington University were a Siemens Biograph 40 PET/CT scanner (n = 1) and a Siemens ECAT HR? PET scanner (n = 49). The scanner used for St. Louis University participants was a Gemini PET/CT scanner (Philips Medical Systems) (n = 1). The St. Louis VAMC participants underwent PET imaging at Washington University. All patients fasted for at least 4 h prior to the PET study. To exclude fasting hyperglycemia, a blood sample to determine the blood glucose level (by glucometer) was obtained prior to FDG injection to ensure a level \200 mg/dl.
The FDG (10 mCi) was injected intravenously. Patients were instructed to minimize talking after administration of FDG until completion of the examination to minimize uptake in the laryngeal muscles. With the patient in a supine position, imaging from the base of the brain to the superior chest was initiated 50 to 60 min following FDG injection. For ECAT HR?, a series of 2-to 5-min transmission scans, centered at the level of the thyroid gland, with the use of 68 Ge/ 68 Ga rod source was performed at each level. Following completion of the transmission scan, a series of 10-to 15-min emission scans was performed over the same anatomic extent. PET images were reconstructed with the use of an ordered-subset expectation maximization iterative algorithm and a 7-mm gaussian filter. Attenuation correction was performed with the segmentation method developed by Xu et al. [7] . For the Biograph 40, the CT imaging parameters were the factory recommended preset low-dose whole-body PET/CT imaging protocol (50 mAs, 120 kV, 0.5 s/rotation, 0.8 pitch) with appropriate adjustments based on patient size and weight. PET images centered at the level of the thyroid gland were obtained, with imaging times of 1-5 min per bed position, depending on the patient's weight. PET images were corrected for scatter, random coincidences, and attenuation; and they were reconstructed using standard algorithms supplied by the scanner's manufacturer. Imaging protocol for the Gemini PET/CT scanner was similar to that for the Biograph 40.
All PET images were evaluated qualitatively by an experienced nuclear medicine radiologist in a routine clinical fashion; it included correlation with other imaging studies if available. The reader was blinded to the final pathologic diagnosis at the time of the reading but was aware that the PET examination was being performed to evaluate a patient with a thyroid nodule that had follicular or indeterminate FNA cytology. The reader characterized the nodule uptake in qualitative terms on an ordinal scale: no, mild, moderate, or marked uptake. Diffuse or focal uptake was also noted. For this analysis, an FDG-PET or FDG-PET/CT study was considered negative if no focal uptake was seen in the nodule of interest.
The FDG uptake in the nodules was evaluated semiquantitatively by calculating maximum standardized uptake values (SUVs), a quantitative measure of uptake. Calculations also were corrected for lean body mass. The SUV is a decay-corrected measurement of activity per unit volume of tissue (nanocuries per milliliter) adjusted for administered activity per unit of body weight (nanocuries per kilogram).
Diagnostic standard
The pathology diagnosis was performed as standard of care for all patients at each institution. Pathologists performing the diagnosis were blinded to the patient's FDG-PET results. The final histopathologic diagnosis served as the standard to which FDG-PET results were compared. Incidental thyroid papillary microcarcinoma in a location other than the indeterminate nodule of interest was not considered a positive finding for comparison with FDG-PET results.
Results
Individual patient characteristics, imaging and pathology data, and PET results are listed in Table 1 . The mean age ± standard deviation (SD) of participants was 49.5 ± 10.6 years (range 22-77 years). Most patients were female (80.4%). Of the 51 lesions, 10 were malignant (19.6%) by pathology analysis. Three patients (5.9%) were found to have thyroid papillary microcarcinoma at sites separate from the lesion of interest by pathologic analysis. One additional patient had two [1 cm foci of papillary thyroid carcinoma contralateral to the lesion of interest. For benign lesions with focal uptake, the mean ± SD SUV max was 1.91 ± 2.64 (range 1.87-11.1). For malignant lesions with focal uptake, the mean ± SD SUV max was 12.7 ± 5.71 (range 2.0-51.9). On univariate analysis, there were no statistically significant differences in age, sex, malignancy status, gross pathology size, or imaging size between the 51 study participants and the 35 who were eligible but refused participation.
Results of FDG-PET compared with final histopathologic diagnosis for all patients are shown in Table 2 . For all lesions, the sensitivity, specificity, positive-predictive value (PPV), and negative-predictive value (NPV) were 80%, 61%, 33%, and 93%, respectively. The 95% CI for the 80% sensitivity was 44% to 97%, and for the 61% specificity it was 49% to 80%.
Eight lesions were found to be \1 cm in greatest dimension by gross pathology despite measurements of C1 cm on preoperative imaging. One lesion did not have gross pathology that correlated with the imaging finding, so no pathology size was reported. Per our inclusion criteria, these lesions would be below the expected resolution of the PET scan to detect. Results for all lesions C1 cm are shown in Table 3 . For these 42 lesions, the sensitivity, specificity, PPV, and NPV were 100%, 59%, 36%, and 100%, respectively. For the sensitivity and specificity regarding the C1 cm lesions, the 95% CIs were (69%, 100%) and (41%, 75%), respectively.
Discussion
These data suggest that FDG-PET is an accurate diagnostic modality for identifying malignancy in thyroid nodules at least 1 cm in diameter and with indeterminate cytology, with 100% sensitivity and NPV in our series. These values were somewhat lower when all lesion sizes were included. Two false-negative results occurred in lesions \1 cm because their size was overestimated on ultrasonography (US) examination. Preoperative US overestimated lesion size in benign and malignant lesions in our data set, leading to the inclusion of eight nodules below the diameter threshold required for accurate detection by PET imaging. This discordance has been previously reported in a large series from the University of Pennsylvania, where 33% of solid thyroid nodules measuring 1.1 to 2.0 cm on US were later found to be B1 cm on gross pathology [8] .
The gross pathology size is obviously not known prior to surgical excision and therefore cannot be used as a selection criterion. However, there may be imaging characteristics that could refine the selection of appropriate patients who might benefit from FDG-PET.
Although our sample size is still somewhat limited, in a post hoc analysis if we excluded predominantly cystic lesions and used a US size cutoff of C1.5 cm we would have eliminated the lesions measured as subcentimeter in diameter by gross pathology. These US criteria, however, were not assessed on a prospective basis in our study population. Accrual of a larger patient pool to our target of 125 patients will provide better statistical power to reassess this observation on final study analysis.
Incidental papillary thyroid carcinomas (PTCs) present a dilemma. This analysis was restricted to evaluating the ability of PET to detect cancer in the nodule of interest. However, four of our patients had PTC found at locations separate from the nodule of interest on pathology analysis. Each of these patients was found to have benign disease in the nodule that underwent FNA. Three of these incidental lesions would be considered papillary microcarcinomas (\1 cm diameter), but one patient had two PTCs (1.7 and 1.2 cm diameter, respectively) contralateral to the nodule of interest. Those two lesions had not been biopsied prior to thyroidectomy despite their visualization on preoperative US and the identification of calcifications within one of the nodules. Clearly, that patient benefited from thyroidectomy for her benign nodule, or her multifocal PTC would have remained undiagnosed and untreated. However, for the purposes of this analysis her test was interpreted as false positive because in her case marked focal PET uptake was seen in her benign nodule, not within her incidental PTCs.
In one recent study, incidental papillary microcarcinomas (\1 cm) undetected by imaging or without suspicious US features of hypoechogenicity and microcalcifications had significantly fewer poor prognostic features on pathology (multifocality, extracapsular extension, lymph node metastasis) than nodules with those US features [9] . The US and histopathologic characteristics of the three papillary microcarcinomas found so far in our study were consistent with those findings. It is unclear what consequences would result for our three patients if these previously undetected papillary microcarcinomas had not been discovered, in the absence of another surgical indication.
The incidental manner of diagnosis may confer some prognostic information. One recent study by Pisanu et al. found that nonincidental diagnosis was an independent poor prognostic factor for nodal metastasis, along with capsular invasion, for papillary microcarcinomas [10] . In that study, patients with an incidental diagnosis of papillary microcarcinoma, after thyroidectomy for another indication, had lower prevalence of central or lateral lymph node involvement (1.4%) than those with microcarcinomas detected prior to surgery (21.0%). Ito et al. [11] reported that more than 70% of patients with known papillary microcarcinomas who chose observation with serial US over For these lesions, sensitivity was 80%, specificity 61%, positive predictive value (PPV) 33%, and negative predictive value (NPV) 93% For these lesions, sensitivity was 100%, specificity 59%, PPV 36%, and NPV 100%
immediate surgery had no increase in size during followup, even in those followed for 5 years. However, papillary microcarcinomas can exhibit aggressive behavior, with recurrence rates up to 20% after thyroid lobectomy as well as metastases to cervical lymph nodes or distant sites, becoming a significant cause of morbidity and in some cases mortality [12] [13] [14] [15] [16] [17] . At this time, we have insufficient data to comment on the accuracy of FDG-PET in the setting of incidental PTCs or papillary microcarcinomas separate from the nodule of interest. In this series, some patients underwent hemithyroidectomy and others underwent near-total thyroidectomy based on their clinical findings and the preferences of the surgeon and patient. Therefore, we cannot know the total number of additional nodules, benign or malignant, that may have been present in all patients. Incidental papillary microcarcinomas are likely to represent a different population than nodules with indeterminate FNA cytology because they have either been undetected or deemed sufficiently low risk to forego biopsy prior to surgery for another indication. Our study was not designed to examine the role of FDG-PET for this lesion population.
One consistent observation among most studies evaluating the utility of FDG-PET for identifying malignancy in this patient population is poor specificity in the setting of high sensitivity. Our study thus far corroborates this finding with PET identifying malignancy in lesions C1 cm in diameter with a sensitivity of 100% but a specificity of only 59%. Additionally, current data indicate that an FDG-PET study demonstrating focal uptake in the nodule of interest provides little or no diagnostic benefit for identifying malignancy. This study also demonstrates a high NPV for FDG-PET to exclude malignancy in these thyroid nodules of indeterminate cytology. This high NPV in combination with high sensitivity makes exclusion of malignancy a more meaningful parameter. Despite poor specificity, the ability of a negative FDG-PET examination to exclude malignancy would be helpful in surgical decision-making as more than 80% of patients with this cytology are currently having thyroid surgery for benign disease. Although data from this interim analysis are encouraging for the utility of FDG-PET in this clinical setting, completion of accrual for this study to a total of 125 patients will add statistical power to the data analysis to generate more meaningful recommendations for future clinical applications.
